AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23064532 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based screening
Number of subjects: 200
Study 19274623 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning Centered Group Psychotherapy (MCGP)
Number of subjects: 90
Study 19274623 — intervention group
Group type: COMPARATOR
Intervention: Supportive Group Psychotherapy (SGP)
Number of subjects: 90
Study 17114889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual-swallow immunotherapy (SLIT) with Juniperus ashei allergen extract
Number of subjects: 76
Study 17114889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 16394701 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg rofecoxib
Number of subjects: 60
Study 16394701 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg naproxen
Number of subjects: 60
Study 16394701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15383182 — intervention group
Group type: EXPERIMENTAL
Intervention: Captodiamine (150 mg/d)
Number of subjects: 81
Study 15383182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 10735891 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin plus hydrocortisone (HC, 40 mg/d)
Number of subjects: 0
Study 10735891 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus hydrocortisone (HC)
Number of subjects: 0
Study 8923333 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg of doxylamine succinate administered orally every 6 h for 17 days
Number of subjects: 48
Study 8923333 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of phenobarbital administered orally every 6 h for 17 days
Number of subjects: 48
Study 8923333 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally every 6 h for 17 days
Number of subjects: 48
Study 1557982 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 1557982 — intervention group
Group type: COMPARATOR
Intervention: No Timolol
Number of subjects: 0
Study 4053337 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow inspiratory flow rates (15-30 l/min)
Number of subjects: 15
Study 4053337 — intervention group
Group type: COMPARATOR
Intervention: Flow rates higher than 70 l/min
Number of subjects: 15
Study 31242792 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol/Glycopyrrolate (IND/GLY) 27.5/15.6 µg twice daily
Number of subjects: 2043
Study 31242792 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol/Glycopyrrolate (IND/GLY)
Number of subjects: 2043
Study 28987994 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta tACS (2.5Hz)
Number of subjects: 24
Study 28987994 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta tACS (5Hz)
Number of subjects: 24
Study 28987994 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 24
Study 26250523 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin α1 (Tα1) plus routine treatment
Number of subjects: 84
Study 26250523 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 84
Study 24081937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg once per day
Number of subjects: 1074
Study 24081937 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice per day
Number of subjects: 1074
Study 21694621 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use (citalopram, sertraline, paroxetine)
Number of subjects: 281
Study 21694621 — intervention group
Group type: COMPARATOR
Intervention: No antidepressant use
Number of subjects: 281
Study 18582178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 18582178 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg MPH
Number of subjects: 65
Study 18582178 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg MPH
Number of subjects: 65
Study 18582178 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg MPH
Number of subjects: 65
Study 18582178 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg MPH
Number of subjects: 65
Study 16538239 — intervention group
Group type: EXPERIMENTAL
Intervention: Olibra fat emulsion (5 g of Olibra fat)
Number of subjects: 28
Study 16538239 — intervention group
Group type: COMPARATOR
Intervention: Control (5 g milk fat)
Number of subjects: 28
Study 12740736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint trained runners
Number of subjects: 3
Study 12740736 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance trained runners
Number of subjects: 3
Study 12740736 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained subjects
Number of subjects: 3
Study 11069454 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light (630 +/- 15 nm)
Number of subjects: 61
Study 11069454 — intervention group
Group type: COMPARATOR
Intervention: Green light (540 +/- 15 nm)
Number of subjects: 61
Study 8836933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) levodopa preparation (100 mg and 200 mg)
Number of subjects: 12
Study 8836933 — intervention group
Group type: COMPARATOR
Intervention: Conventional immediate-release (IR) levodopa preparation (100 mg)
Number of subjects: 12
Study 8836933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SR and IR levodopa (70% SR and 30% IR)
Number of subjects: 12
Study 1417666 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E administration at a dose of 100 mg daily for three weeks
Number of subjects: 32
Study 1417666 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A administration
Number of subjects: 32
Study 3883876 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure compression stocking
Number of subjects: 303
Study 3883876 — intervention group
Group type: COMPARATOR
Intervention: Standard bandaging technique
Number of subjects: 303
Study 30915676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer education delivered by bilingual community health educators
Number of subjects: 1488
Study 30915676 — intervention group
Group type: COMPARATOR
Intervention: General health education including information about cancer screening
Number of subjects: 1488
Study 29895599 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Clotting Time (ACT) >230 s
Number of subjects: 3275
Study 29895599 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT ≥250 s (femoral approach)
Number of subjects: 3275
Study 29895599 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT ≥290 s (radial approach)
Number of subjects: 3275
Study 27716694 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Directed Therapy (GDT)
Number of subjects: 130
Study 27716694 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study 24474602 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+P (treatment as usual combined with clinician-lead cognitive behavioural treatment for perfectionism)
Number of subjects: 61
Study 24474602 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 61
Study 21965526 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (direct renin inhibitor), n=423
Number of subjects: 214
Study 21965526 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (direct renin inhibitor)
Number of subjects: 214
Study 21965526 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=397
Number of subjects: 214
Study 21965526 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 214
Study 19147800 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 742
Study 19147800 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Behaviour and Network Therapy (SBNT)
Number of subjects: 742
Study 19147800 — intervention group
Group type: COMPARATOR
Intervention: Both MET and SBNT
Number of subjects: 742
Study 19147800 — intervention group
Group type: EXPERIMENTAL
Intervention: Clients
Number of subjects: 742
Study 19147800 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists
Number of subjects: 742
Study 17398122 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 3244
Study 17398122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3244
Study 15198280 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving textbox instruments
Number of subjects: 5
Study 15198280 — intervention group
Group type: COMPARATOR
Intervention: Heading indicator (control)
Number of subjects: 5
Study 15198280 — intervention group
Group type: EXPERIMENTAL
Intervention: Workload
Number of subjects: 5
Study 15198280 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 5
Study 11765586 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 × 850 mg/day)
Number of subjects: 2
Study 11765586 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (3 × 100 mg/day)
Number of subjects: 2
Study 11765586 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modifications (control group)
Number of subjects: 2
Study 9164900 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise
Number of subjects: 0
Study 9164900 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study 8388880 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone
Number of subjects: 7
Study 8388880 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine/naloxone
Number of subjects: 7
Study 3828166 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bilateral intercostal blockade
Number of subjects: 0
Study 3828166 — intervention group
Group type: COMPARATOR
Intervention: Conventional i.v. narcotics
Number of subjects: 0
Study 30602756 — intervention group
Group type: COMPARATOR
Intervention: tIOL
Number of subjects: 80
Study 30602756 — intervention group
Group type: EXPERIMENTAL
Intervention: PCRI
Number of subjects: 80
Study 28642330 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP target of <120 mm Hg (intensive group)
Number of subjects: 2646
Study 28642330 — intervention group
Group type: COMPARATOR
Intervention: Systolic BP target of <140 mm Hg (standard group)
Number of subjects: 2646
Study 26614412 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR (self-expanding bioprosthesis)
Number of subjects: 742
Study 26614412 — intervention group
Group type: COMPARATOR
Intervention: SAVR (surgical aortic valve replacement)
Number of subjects: 742
Study 26614412 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 742
Study 26614412 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 742
Study 26614412 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients with severe PPM (TAVR + SAVR)
Number of subjects: 742
Study 24450891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab
Number of subjects: 1090
Study 24450891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (0.5 mg/kg)
Number of subjects: 1090
Study 24450891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (1.0 mg/kg)
Number of subjects: 1090
Study 24450891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1090
Study 21848927 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum treatment
Number of subjects: 60
Study 21848927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19410984 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone metacarpophalangeal joint arthroplasty (SMPA)
Number of subjects: 163
Study 19410984 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 163
Study 17138955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 420
Study 15871755 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal counseling (A)
Number of subjects: 26
Study 15871755 — intervention group
Group type: COMPARATOR
Intervention: Verbal counseling with emphasis on Turbuhaler position during priming (B)
Number of subjects: 26
Study 15871755 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented verbal counseling plus physical demonstration (C)
Number of subjects: 26
Study 12475829 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin, 40 mg/d
Number of subjects: 150
Study 12475829 — intervention group
Group type: COMPARATOR
Intervention: Heparin, 5,000 U bid
Number of subjects: 150
Study 10597852 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 intrameniscal signal abnormalities in gymnasts
Number of subjects: 24
Study 8950073 — intervention group
Group type: EXPERIMENTAL
Intervention: Elgodipine (64 micrograms/kg, i.v.)
Number of subjects: 22
Study 8950073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 1683354 — intervention group
Group type: EXPERIMENTAL
Intervention: Etilefrin (Effortil)
Number of subjects: 33
Study 1683354 — intervention group
Group type: COMPARATOR
Intervention: Ornithine 8 vasopressin (Por 8)
Number of subjects: 33
Study 6957982 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg PIR twice daily
Number of subjects: 20
Study 6957982 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20
Study 31207152 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Zoster Vaccine (LZV)
Number of subjects: 1146
Study 31207152 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 5 mg BID
Number of subjects: 1146
Study 31207152 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 5 mg BID plus MTX
Number of subjects: 1146
Study 31207152 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA) 40 mg every other week plus MTX
Number of subjects: 1146
Study 31207152 — intervention group
Group type: EXPERIMENTAL
Intervention: LZV
Number of subjects: 1146
Study 30292744 — intervention group
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Number of subjects: 452
Study 30292744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study 28134783 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support
Number of subjects: 756
Study 28134783 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial reimbursement
Number of subjects: 756
Study 25228065 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused decision aid with affective content
Number of subjects: 148
Study 25228065 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-focused decision aid without affective content
Number of subjects: 148
Study 25228065 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no affective content)
Number of subjects: 148
Study 23407784 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndrome 1
Number of subjects: 0
Study 23407784 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndrome 2
Number of subjects: 0
Study 23407784 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndrome 3
Number of subjects: 0
Study 23407784 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 syndrome groups
Number of subjects: 0
Study 23407784 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21158931 — intervention group
Group type: EXPERIMENTAL
Intervention: All-ceramic crowns
Number of subjects: 20
Study 21158931 — intervention group
Group type: COMPARATOR
Intervention: Porcelain-fused-to-ceramic (PFM) crowns
Number of subjects: 20
Study 19140095 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg verapamil daily for 6 days
Number of subjects: 18
Study 17712295 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT Ultrasound (Nomos, Sewicky, PA)
Number of subjects: 15
Study 17712295 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 15
Study 15562168 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive loading (IRL) set at 80% of maximum inspiratory pressure, three days a week for 10 weeks
Number of subjects: 15
Study 15562168 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PLA) performing the same training procedure with minimal resistance
Number of subjects: 15
Study 15562168 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) performing no IRL during the 10 week study period
Number of subjects: 15
Study 10750752 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP (human atrial natriuretic peptide) administered for 24 hours from the start of CPB
Number of subjects: 40
Study 10750752 — intervention group
Group type: COMPARATOR
Intervention: non-hANP group (control)
Number of subjects: 40
Study 8669670 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 75
Study 8669670 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.4 mg/kg)
Number of subjects: 75
Study 8669670 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg)
Number of subjects: 75
Study 1529939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables (administered for 12 weeks)
Number of subjects: 621
Study 1529939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fruits and vegetables)
Number of subjects: 621
Study 4074606 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg oral solution
Number of subjects: 7
Study 4074606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3304706 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (5.5 mg iv as a bolus divided into four doses during the first 2 hours followed by 10 mg orally twice daily for 1 month)
Number of subjects: 200
Study 3304706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 3304706 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 200
Study 30197041 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-TRICOM (PROSTVAC)
Number of subjects: 0
Study 30197041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28288611 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (twice weekly for 15 weeks)
Number of subjects: 43
Study 25774705 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycaemic-index (LGI) diet and Policaptil Gel Retard
Number of subjects: 133
Study 25774705 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycaemic-index (LGI) diet
Number of subjects: 133
Study 25774705 — intervention group
Group type: COMPARATOR
Intervention: Energy-restricted diet (ERD)
Number of subjects: 133
Study 23690414 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate + Nursing Telephone Intervention (MP+NTI)
Number of subjects: 141
Study 23690414 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo + Nursing Telephone Intervention (PL+NTI)
Number of subjects: 141
Study 23690414 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate + Control Telephone Intervention (MP+CTI)
Number of subjects: 141
Study 23690414 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo + Control Telephone Intervention (PL+CTI)
Number of subjects: 141
Study 23690414 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 141
Study 23690414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 23690414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Telephone Intervention (NTI)
Number of subjects: 141
Study 20534951 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution mixed with orange juice
Number of subjects: 0
Study 20534951 — intervention group
Group type: COMPARATOR
Intervention: Oral itraconazole solution with water
Number of subjects: 0
Study 18503623 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 3 mg/mL
Number of subjects: 45
Study 18503623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 4.5 mg/mL
Number of subjects: 45
Study 18503623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 3 mg/mL
Number of subjects: 45
Study 16803518 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomerase activity in tumor
Number of subjects: 33
Study 16803518 — intervention group
Group type: COMPARATOR
Intervention: Telomerase activity in anterior vaginal margin (AVM) and posterior vaginal margin (PVM)
Number of subjects: 33
Study 16803518 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomerase activity in PVM
Number of subjects: 33
Study 16803518 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HPV in AVM or PVM
Number of subjects: 33
Study 12689781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cable-released falls in older adults
Number of subjects: 20
Study 12689781 — intervention group
Group type: COMPARATOR
Intervention: Self-initiated falls in older adults
Number of subjects: 20
Study 12689781 — intervention group
Group type: COMPARATOR
Intervention: Cable-released falls in young males
Number of subjects: 20
Study 12689781 — intervention group
Group type: COMPARATOR
Intervention: Self-initiated falls in young males
Number of subjects: 20
Study 11119402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0
Study 11119402 — intervention group
Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study 9089669 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 micrograms kg‐1 in 10 ml infused intravenously over 10 min) at 20 degrees C
Number of subjects: 8
Study 9089669 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 micrograms kg‐1 in 10 ml infused intravenously over 10 min) at 40 degrees C
Number of subjects: 8
Study 9089669 — intervention group
Group type: COMPARATOR
Intervention: High ambient temperature (40 degrees C)
Number of subjects: 8
Study 9089669 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline infused intravenously over 10 min) at 20 degrees C
Number of subjects: 8
Study 9089669 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline infused intravenously over 10 min) at 40 degrees C
Number of subjects: 8
Study 1304177 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% triclosan and 2% copolymer of methoxyethylene and maleic acid)
Number of subjects: 159
Study 1304177 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 159
Study 4013627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal block (i.c.b.) after subcostal incision
Number of subjects: 94
Study 4013627 — intervention group
Group type: EXPERIMENTAL
Intervention: Second intercostal block (i.c.b.) 8 hours after the first one
Number of subjects: 94